Higher-valency pneumococcal conjugate vaccines in elderly, taking into account indirect protection and serotype replacement from childhood vaccination programs: A cost-effectiveness study

de Boer, PTvan Werkhoven, CHvan Hoek, AJKnol, MSanders, EAMWallinga, Jde Melker, HESteens, A2023-06-162023-06-162023http://hdl.handle.net/10029/626769enHigher-valency pneumococcal conjugate vaccines in elderly, taking into account indirect protection and serotype replacement from childhood vaccination programs: A cost-effectiveness studyPreprint